Publications highlight the safety and tolerability of Radspherin for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
All dose levels of Radspherin were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin is currently being evaluated in two ongoing Phase 1 trials for
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming
Company adds experienced clinical development expert to its board of directors Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary